Recombinant tissue plasminogen activator (rtPA) and stroke unit for acute ischaemic stroke in developing countries, are they cost-effective?

International Journal of Stroke

Volumn 7, Issue 7, 2012, Pages

  Shahtaheri, Rahil Alsadat ^a   Borhani Haghighi, Afshin ^a,b   Safari, Anahid ^c   Cruz Flores, Salvador ^d  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

BRAIN ISCHEMIA; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEVELOPING COUNTRY; FIBRINOLYTIC THERAPY; HEALTH CARE COST; HUMAN; INDIA; IRAN; LETTER; PRIORITY JOURNAL; PRODUCTIVITY; STROKE PATIENT; STROKE UNIT;

COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HOSPITAL DEPARTMENTS; HUMANS; RECOMBINANT PROTEINS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84866512764     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2012.00892.x     Document Type: Letter

References (5)

1. Sandercock P, Berge E, Dennis M etal. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 2004; 35:1490-1497.
2. Epifanov Y, Dodel R, Haacke C etal. Costs of acute stroke care on regular neurological wards: a comparison with stroke unit setting. Health Policy 2007; 81:339-349.
3. Marini C, Russo T, Felzani G. Incidence of stroke in young adults: a review. Stroke Res Treat 2010; 2011:535672.
4. Hamad A, Sokrab TE, Momeni S, Mesraoua B, Lingren A. Stroke in Qatar: a one-year, hospital-based study. J Stroke Cerebrovasc Dis 2001; 10:236-241.
5. Ghandehari K. Barriers of thrombolysis therapy in developing countries. Stroke Res Treat 2011; 2011:686797.